Article Versions Notes

Schultheiss H-P, Bock T, Pietsch H, Aleshcheva G, Baumeier C, Fruhwald F, Escher F. Nucleoside Analogue Reverse Transcriptase Inhibitors Improve Clinical Outcome in Transcriptional Active Human Parvovirus B19-Positive Patients. Journal of Clinical Medicine. 2021; 10(9):1928. https://doi.org/10.3390/jcm10091928

Schultheiss, Heinz-Peter, Thomas Bock, Heiko Pietsch, Ganna Aleshcheva, Christian Baumeier, Friedrich Fruhwald, and Felicitas Escher. 2021. "Nucleoside Analogue Reverse Transcriptase Inhibitors Improve Clinical Outcome in Transcriptional Active Human Parvovirus B19-Positive Patients" Journal of Clinical Medicine 10, no. 9: 1928. https://doi.org/10.3390/jcm10091928

Schultheiss, H.-P., Bock, T., Pietsch, H., Aleshcheva, G., Baumeier, C., Fruhwald, F., & Escher, F. (2021). Nucleoside Analogue Reverse Transcriptase Inhibitors Improve Clinical Outcome in Transcriptional Active Human Parvovirus B19-Positive Patients. Journal of Clinical Medicine, 10(9), 1928. https://doi.org/10.3390/jcm10091928